GMDA Gamida Cell Ltd.

14
-0.22  -2%
Previous Close 14.22
Open 14.25
Price To Book -70
Market Cap 339120656
Shares 24,222,904
Volume 10,747
Short Ratio
Av. Daily Volume 16,384

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 updated data announced February 21, 2019 noted 3/12 CRs.
NAM-NK
Non-Hodgkin lymphoma; Multiple myeloma
Phase 1/2 preliminary data due 1H 2019.
NiCord
Severe aplastic anemia
Phase 3 top-line data due 1H 2020.
NiCord
Acute myeloid leukemia

Latest News

  1. Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
  2. Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
  3. Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
  4. Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
  5. Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
  6. Gamida Cell Announces 2019 Goals and Provides Company Update
  7. Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
  8. Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting
  9. Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
  10. Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
  11. Gamida Cell Announces Pricing of Initial Public Offering
  12. StoneCo IPO Soars As Trading Begins, Yeti IPO Falls Flat
  13. Brazil's StoneCo, Yeti Holdings Headline List Of IPOs This Week